logo

ABCL’s Debt-to-Equity Ratio at 0.07: What It Means for AbCellera Biologics Inc’s Future

ZM Stock

The market performance of AbCellera Biologics Inc’s stock has been turbulent in recent times. Over the last year, the company’s stock reached its highest point at $5.62 on 01/30/24, while the lowest value for the same duration was $2.34 on 09/10/24.

52-week price history of ABCL Stock

Studying a stock’s 52-week price history, which includes both low and high prices, can help gauge its current status and potential future performance. AbCellera Biologics Inc’s current trading price is -41.01% away from its 52-week high, while its distance from the 52-week low is 41.97%. The stock’s price range during the 52-week period has remained between $2.34 and $5.62. In the Healthcare sector, the company’s shares saw a trading volume of around 2.34 million for the day, which was evidently lower than the average daily volume of 3.01 million over the past three months.

Market Capitalization and Financial Performance: An In-Depth Look

AbCellera Biologics Inc (ABCL) has experienced a quarterly rise of 21.88% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 979.14M and boasts a workforce of 586 employees.

Making Sense of Trading Volume and Moving Average Data

Based on Barchart.com data, the company’s moving average over the 100-day period was 2.82, with a change in price of +0.82. Similarly, AbCellera Biologics Inc recorded 2,592,800 in trading volume during the last 100 days, posting a change of +32.34%.

Examining ABCL’s Debt-to-Equity Ratio: What You Need to Know

The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for ABCL stands at 0.07. Similarly, the long-term debt-to-equity ratio is also 0.06.

ABCL Stock Stochastic Average

As of today, AbCellera Biologics Inc’s raw stochastic average for the last 50 days stands at 68.92%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 62.70%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 62.34% and 68.47%, respectively.

ABCL Stock Price Performance Analysis

Investors’ outlook regarding the stock price performance over the year has been split, with some feeling optimistic and others feeling pessimistic, as it’s been a mixed bag. Until today this year the stock’s price performance recorded an increase of 13.14%. However, over the last six months, the performance has been weaker by 2.63%. The price of ABCL increased 9.41% over the last 30 days. And in the last five days, it has fallen by -6.09%.

Most Popular